Bildkälla: Stockfoto

Orphazyme: Further details on path forward in US - Redeye

Redeye comments on today’s updated schedule for Orphazyme’s planned NDA resubmission with arimoclomol in NPC.

Redeye comments on today’s updated schedule for Orphazyme’s planned NDA resubmission with arimoclomol in NPC.
Börsvärldens nyhetsbrev
ANNONSER